Source Bioscience (LON:SBS), the healthcare and pharma services business, has launched a new, enhanced website encompassing its entire spectrum of life science activities - www.lifesciences.sourcebioscience.com. The service has been designed to give customers extra functionality and the ability to order sequencing services, clones, antibodies and other research tools from one combined website. The company said it hoped the new service would allow it to increase cross selling and attract new customers.

The website is the first of its kind in the industry, with a combined offering that allows customers to order everything they need from one, easy to navigate site, saving time and money. It boasts more than 90,000 high quality antibodies with enhanced search facilities, 16 million DNA clones coupled with the company’s proprietary CloneHunter search engine together with DNA sequencing ordering and information on the full suite of genomic services the company offers including next generation sequencing.

Dr Nick Ash, the managing director of Source Bioscience, said: “We have an exceptional product and services portfolio with a breadth and depth that is possibly unique in the life science research sector. It is a great strength of our business and one we are very keen to build on. From a single site, the new website offers life science customers access to many of the products and services they require including sequencing, clones, antibodies and other genomic reagents and biomolecular tools. This will save our customers time, as well as money. By removing the need to shop around, we believe that we can increase cross selling and attract new customers.”

In the six months to June 31, 2010, Source BioScience delivered a modest rise in revenue to £6.9m and a pre-tax profit flat at £0.1m. Those figures compared well against an exceptional performance in the first half of 2009, when the death of reality TV star Jade Goody triggered a surge in demand for cervical screening – one of the company’s specialisations. A series of contract wins, including the award of a cervical screening deal in Wales worth £5.0m over five years have kept up the company’s strong momentum. Click here to read a Stockopedia interview with Nick Ash.

Unlock the rest of this article with a 14 day trial

Unlock with Email
Unlock with Google

Already have an account?
Login here